Related Experiment Video

Updated: Aug 20, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.6K

Deep brain stimulation in dopa-responsive parkinsonism - Look out for red flags

Vikram V Holla1, Bharat Kumar Surisetti1, Shweta Prasad2

  • 1Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, 560029, India.

Parkinsonism & Related Disorders
|November 21, 2022
PubMed
Summary

No abstract available in PubMed .

Keywords:
AP5Z1Deep brain stimulationDopa-responsive parkinsonismSPG48

More Related Videos

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
07:14

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

14.8K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K

Related Experiment Videos

Last Updated: Aug 20, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.6K
A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
07:14

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

14.8K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

347
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
347
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

665
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
665

Articles linked to this work by shared authors, journal, and citation graph.

Fatigue in Parkinson's Disease: A Cross-Sectional Study of Prevalence and Clinical Correlates.

Annals of Indian Academy of Neurology·2026

Peripheral and central inflammation in progressive supranuclear palsy syndrome: an immunological and imaging neuroinflammation study.

Frontiers in immunology·2026

Botulinum Neurotoxin for Postoperative Facial Nerve Paralysis: A Technical Note.

Neurology India·2026

Whole-genome sequencing of 197 cases with Parkinson's disease reveals novel pathogenic variants in the Indian population.

NPJ Parkinson's disease·2026

Prevalence and state-dependent patterns of non-motor fluctuations in Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996)·2026

Chronology of Non-Motor Symptoms in 100 Patients with Advanced PD of 10 Years' Duration: Pre- versus Post-Motor Period.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026

Longitudinal changes in DTI-ALPS index are associated with clinical progression and brainstem atrophy in spinocerebellar ataxia type 3.

Parkinsonism & related disorders·2026

Health phenome of Parkinson's patients reveals prominent mood-sleep cluster.

Parkinsonism & related disorders·2026

Frequency and outcome of PEG tube implantations in hospitalized Parkinson's disease patients.

Parkinsonism & related disorders·2026

The acute effects of a single session of intermittent hypoxia on blood biomarker concentrations and sleep parameters in people with Parkinson's disease: A randomized, double-blind, crossover trial.

Parkinsonism & related disorders·2026

A framework for multidisciplinary management of autonomic dysfunction in Parkinson disease.

Parkinsonism & related disorders·2026

MANAGE-PD and clinician recommendations for device-aided therapy in Parkinson's disease: Insights from a Turkish tertiary movement disorders cohort.

Parkinsonism & related disorders·2026

Comparative Study of Medication Adherence and Glycemic Control in Type 2 Diabetes Mellitus Patients on Oral Hypoglycemics versus Insulin Therapy.

Journal of pharmacy & bioallied sciences·2026

Drug Utilization Pattern and Maternal Outcomes of Obstetric Medications in Antenatal and Postnatal Women at a Tertiary Care Hospital.

Journal of pharmacy & bioallied sciences·2026

Efficacy and Safety of Pioglitazone in Improving Cognitive Function among Patients with Impaired Cognition as an Add-On Therapy: A Study Protocol.

Biomedicine hub·2026

Assessment of Drug Therapy Awareness, Medication Adherence, and Predictors of Knowledge, Attitude, and Practice on Diabetic Complications in Type 2 Diabetes Mellitus: A Cross-Sectional Study.

Journal of pharmacy & bioallied sciences·2026

Evaluation of Pharmacovigilance Reporting Patterns and Adverse Drug Reactions in a Tertiary Care Teaching Hospital.

Journal of pharmacy & bioallied sciences·2026

Pharmacodynamic modeling of colistin and imipenem against in vitro Pseudomonas aeruginosa biofilms.

Biofilm·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us